Enjaymo
Recordati Acquires Sanofi’s Rare Disease Drug Enjaymo in $825M Deal
Recordati, Sanofi, Enjaymo, rare disease, cold agglutinin disease (CAD), pharmaceutical acquisition
Actionable Insights Powered by AI
Recordati, Sanofi, Enjaymo, rare disease, cold agglutinin disease (CAD), pharmaceutical acquisition